Scholar Rock Holding annual r&d spending
2017
2018
2019
2020
2021
2022
2023
2024
2025
Scholar Rock Holding R&D Spending Growth & History (SRRK)
Scholar Rock Holding's r&d spending was $208.4M for fiscal 2025.
View full Scholar Rock Holding company overviewScholar Rock Holding annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $208.4M | $23.9M | +12.95% |
| 2024 | 2024-12-31 | $184.6M | $62.6M | +51.39% |
| 2023 | 2023-12-31 | $121.9M | $118.2M | +3194.59% |
| 2022 | 2022-12-31 | $3.7M | $0 | 0.00% |
| 2021 | 2021-12-31 | $3.7M | −$70.4M | −95.00% |
| 2020 | 2020-12-31 | $74.1M | $19.8M | +36.60% |
| 2019 | 2019-12-31 | $54.2M | $17.9M | +49.32% |
| 2018 | 2018-12-31 | $36.3M | $16.4M | +82.06% |
| 2017 | 2017-12-31 | $19.9M | — | — |
Scholar Rock Holding quarterly r&d spending
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $58.2M | −$4.2M | −6.68% |
| Q1 2026 | 2026-03-31 | $51.8M | $3.1M | +6.44% |
| Q4 2025 | 2025-12-31 | $46.9M | −$3.5M | −6.93% |
| Q3 2025 | 2025-09-30 | $50.5M | $1.8M | +3.63% |
| Q2 2025 | 2025-06-30 | $62.4M | $20.0M | +47.27% |
| Q1 2025 | 2025-03-31 | $48.7M | $5.6M | +12.96% |
| Q4 2024 | 2024-12-31 | $50.4M | $15.4M | +44.06% |
| Q3 2024 | 2024-09-30 | $48.7M | $18.4M | +60.59% |
| Q2 2024 | 2024-06-30 | $42.4M | $15.5M | +57.71% |
| Q1 2024 | 2024-03-31 | $43.1M | $13.4M | +44.93% |
| Q4 2023 | 2023-12-31 | $35.0M | — | — |
| Q3 2023 | 2023-09-30 | $30.3M | −$3.1M | −9.15% |
| Q2 2023 | 2023-06-30 | $26.9M | −$5.2M | −16.23% |
| Q1 2023 | 2023-03-31 | $29.7M | $369,000 | +1.26% |
| Q3 2022 | 2022-09-30 | $33.4M | $2.1M | +6.80% |
| Q2 2022 | 2022-06-30 | $32.1M | $6.5M | +25.27% |
| Q1 2022 | 2022-03-31 | $29.4M | $6.8M | +30.23% |
| Q3 2021 | 2021-09-30 | $31.3M | $12.9M | +70.08% |
| Q2 2021 | 2021-06-30 | $25.6M | $8.6M | +50.63% |
| Q1 2021 | 2021-03-31 | $22.5M | $5.6M | +33.41% |
| Q4 2020 | 2020-12-31 | $21.8M | $7.7M | +54.86% |
| Q3 2020 | 2020-09-30 | $18.4M | $2.7M | +17.10% |
| Q2 2020 | 2020-06-30 | $17.0M | $3.3M | +23.93% |
| Q1 2020 | 2020-03-31 | $16.9M | $6.2M | +57.39% |
| Q4 2019 | 2019-12-31 | $14.1M | $3.9M | +38.92% |
| Q3 2019 | 2019-09-30 | $15.7M | $7.6M | +94.75% |
| Q2 2019 | 2019-06-30 | $13.7M | $2.3M | +20.05% |
| Q1 2019 | 2019-03-31 | $10.7M | $4.0M | +60.26% |
| Q4 2018 | 2018-12-31 | $10.1M | — | — |
| Q3 2018 | 2018-09-30 | $8.1M | $3.3M | +68.71% |
| Q2 2018 | 2018-06-30 | $11.4M | $6.7M | +142.50% |
| Q1 2018 | 2018-03-31 | $6.7M | — | — |
| Q3 2017 | 2017-09-30 | $4.8M | — | — |
| Q2 2017 | 2017-06-30 | $4.7M | — | — |
Scholar Rock Holding r&d spending trends
Over the last five fiscal years, Scholar Rock Holding's r&d spending increased from $74.1M to $208.4M, a change of $134.4M. The latest reported quarter, Q2 2026, shows $58.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scholar Rock Holding source filings ↗Community posts
Scholar Rock wins FDA approval for muscle-targeted SMA treatment
Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...